Early reduction of immune activation in lymphoid tissue following highly active HIV therapy. NLM AIDSLINE Important note: Information in this article was accurate in 1999. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


Early reduction of immune activation in lymphoid tissue following highly active HIV therapy.

AIDS. 1998 Jul 30;12(11):F123-9. Unique Identifier : AIDSLINE MED/98372107
Andersson J; Fehniger TE; Patterson BK; Pottage J; Agnoli M; Jones P; Behbahani H; Landay A; Division of Infectious Diseases, Karolinska Institute, Stockholm,; Sweden.


Abstract: OBJECTIVE: To evaluate immune reconstitution within HIV-infected lymphoid tissue during highly active antiretroviral therapy (HAART). DESIGN AND METHODS: In situ cellular responses were studied in sequential tonsillar biopsies in three asymptomatic HIV-infected (CD4 cells greater than 400 x 10(6)/l) antiretroviral treatment-naive volunteers enrolled in a clinical trial to determine the early effect of HAART. Computerized image analysis was used to study immunohistochemically stained sequential tonsil sections for the patterns of local cytokine production, chemokine receptor expression and cellular distribution. Replicate quantitative assessments of samples before and after 4 weeks of therapy were used for the evaluation of drug effects and compared with four uninfected controls. Tonsillar HIV proviral-DNA was determined by fluorescent in situ 5'-nuclease assay. RESULTS: HIV-infected tonsil tissue was characterized by extensive pro-inflammatory and type 1 cytokine expression. A five- to 15-fold elevation of interleukin (IL)-1 alpha, IL-12, IL-2 and interferon (IFN)-gamma protein expression was found compared with controls, and each encompassed a mean of at least 4.5% of the tissue compartment. This was reduced by 20-90% in all individuals after 4 weeks of HAART. In contrast, type 2 cytokine expression (IL-4, IL-10), plus tumour necrosis factor (TNF)-alpha, remained low throughout the study. HAART reduced, by 40%, the expression of HIV co-receptors, CCR5 and CXCR4, which initially were elevated four to six times over the control values. In addition, the myelomonocytic inflammatory proteins, CD68 and calprotectin, diminished by 26-83% after therapy. The HIV RNA was reduced to undetectable levels in plasma by HAART. However, a large pool of tonsil cells (2-7%), remained HIV DNA positive after 4 weeks of therapy. CONCLUSIONS: Although immune activation may be the direct consequence of HIV replication, HAART-associated reconstitution begins with a reduction in inflammatory cytokine production which precedes the elimination of local proviral reservoirs.
Keywords: JOURNAL ARTICLE Anti-HIV Agents/*THERAPEUTIC USE Cytokines/*BIOSYNTHESIS CD8-Positive T-Lymphocytes/CYTOLOGY Drug Therapy, Combination Human HIV Seropositivity/*DRUG THERAPY/*IMMUNOLOGY/VIROLOGY Lymphoid Tissue/CYTOLOGY/IMMUNOLOGY/VIROLOGY Monocytes/CYTOLOGY Receptors, CCR5/*BIOSYNTHESIS Receptors, CXCR4/*BIOSYNTHESIS Support, Non-U.S. Gov't Support, U.S. Gov't, P.H.S. Time Factors Tonsil/*IMMUNOLOGY/PATHOLOGY/VIROLOGY Viral LoadKWDjournalarticleanti-hivagents/KWDtherapeuticusecytokines/KWDbiosynthesiscd8-positivet-lymphocytes/cytologydrugtherapy,combinationhumanhivseropositivity/KWDdrugtherapy/KWDimmunology/virologylymphoidtissue/cytology/immunology/virologymonocytes/cytologyreceptors,ccr5/KWDbiosynthesisreceptors,cxcr4/KWDbiosynthesissupport,non-uKWDsKWDgov'tsupport,uKWDsKWDgov't,pKWDhKWDsKWDtimefactorstonsil/KWDimmunology/pathology/virologyviralload
990130
A9911071

Copyright © 1999 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1999. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1999. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .